Axovant Sciences (AXON) Tops Q4 EPS by 4c; Raises Outlook

Axovant Sciences (NASDAQ: AXON) reported Q4 EPS of $0.40, $0.04 better than the analyst estimate of $0.36. Revenue for the quarter came in at $226 million versus the consensus estimate of $180.96 million.

GUIDANCE:

Axovant Sciences sees FY2021 revenue of $740-780 million, versus the consensus of $742.24 million.

For earnings history and earnings-related data on Axovant Sciences (AXON) click here.

You May Also Be Interested In

• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
• Truist Securities Reiterates Buy Rating on Five9, Inc (FIVN)
• CMA CGM buys FedEx Supply Chain unit for $1.4B in cash deal